These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles. Locatelli F; Del Vecchio L; Violo L; Pontoriero G Expert Opin Drug Saf; 2014 May; 13(5):551-61. PubMed ID: 24702470 [TBL] [Abstract][Full Text] [Related]
23. Use of Phosphorus Binders among Non-Dialysis Chronic Kidney Disease Patients and Mortality Outcomes. Bhandari SK; Liu IA; Kujubu DA; Huynh T; Behayaa H; Kovesdy CP; Kalantar-Zadeh K; Jacobsen SJ; Sim JJ Am J Nephrol; 2017; 45(5):431-441. PubMed ID: 28445887 [TBL] [Abstract][Full Text] [Related]
24. Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis. Mason MA; Shepler BM Pharmacotherapy; 2010 Jul; 30(7):741-8. PubMed ID: 20575637 [TBL] [Abstract][Full Text] [Related]
25. Iron-based phosphate binders: a paradigm shift in the treatment of hyperphosphatemic anemic CKD patients? Locatelli F; Del Vecchio L J Nephrol; 2017 Dec; 30(6):755-765. PubMed ID: 28717990 [TBL] [Abstract][Full Text] [Related]
26. Practice patterns of phosphate binder use and their associations with mortality in chronic kidney disease. Navaneethan SD; Sakhuja A; Arrigain S; Sharp J; Schold JD; Nally JV Clin Nephrol; 2014 Jul; 82(1):16-25. PubMed ID: 24887302 [TBL] [Abstract][Full Text] [Related]
27. Current and potential treatment options for hyperphosphatemia. Carfagna F; Del Vecchio L; Pontoriero G; Locatelli F Expert Opin Drug Saf; 2018 Jun; 17(6):597-607. PubMed ID: 29783873 [TBL] [Abstract][Full Text] [Related]
28. Economic Evaluation of Sevelamer versus Calcium-based Binders in Treating Hyperphosphatemia among Patients with End-stage Renal Disease in China. Yang L; Chuen Tan S; Chen C; Wang X; Li X; Yang X Clin Ther; 2016 Nov; 38(11):2459-2467.e1. PubMed ID: 27751671 [TBL] [Abstract][Full Text] [Related]
37. Non-calcium-containing phosphate binders: comparing efficacy, safety, and other clinical effects. Frazão JM; Adragão T Nephron Clin Pract; 2012; 120(2):c108-19. PubMed ID: 22555359 [TBL] [Abstract][Full Text] [Related]
38. Phosphate binders, cardiovascular calcifications and mortality: do we need another survival study with sevelamer? Negri AL J Nephrol; 2010; 23(6):653-7. PubMed ID: 20349415 [TBL] [Abstract][Full Text] [Related]
39. Moderator's view: Phosphate binders in chronic kidney disease patients: a clear 'No' at the moment, but stay tuned. Zoccali C; Mallamaci F Nephrol Dial Transplant; 2016 Feb; 31(2):196-9. PubMed ID: 26681749 [TBL] [Abstract][Full Text] [Related]
40. Dietary calcium intake does not meet the nutritional requirements of children with chronic kidney disease and on dialysis. McAlister L; Silva S; Shaw V; Shroff R Pediatr Nephrol; 2020 Oct; 35(10):1915-1923. PubMed ID: 32385527 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]